top of page
Beamtree Holdings Ltd

Beamtree Holdings Ltd – Fund Manager Investment Commentary & Insights

ASX:BMT

Health Care Technology

Fund Manager Summary on Beamtree Holdings Ltd (ASX:BMT)

Beamtree Holdings Ltd (ASX:BMT) has shown notable recovery in its share price, rising roughly 33% following a robust Q3 trading update, which included a critical partnership with the NHS in the UK and renewed contracts that solidify revenue streams in Ireland and Saudi Arabia. Fund managers emphasize the company’s positive momentum, notably its projected annual recurring revenue (ARR) growth of over 20% for FY25 and a target of $60 million ARR by the close of 2026. However, risks remain, particularly due to recent price volatility and market pressures observed since late March. Investors are encouraged to consider these operational advancements alongside the existing challenges, as Beamtree positions itself within a growing healthcare software sector.

Commentary From The Managers

There are 4 insights from 1 fund managers regarding their investment in Beamtree Holdings Ltd (ASX:BMT) available on Thesis Tracker.

Unlock Updates With ThesisTracker Pro

Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.

Updates are made available to members within 12 hours of being released. ​The completeness, accuracy or current status of the investments referenced are not guaranteed. 

Commentary From The Managers

The completeness, accuracy or current status of the investments referenced are not guaranteed. 

Investment Ideas Scanner

Why Saville Capital backs Hydration Pharmaceuticals (ASX:HPC) — May sales +34%

Mesoblast (ASX:MSB): Ryoncil FDA approval — fund managers' views

Why fund managers bought Vinyl Group (ASX:VNL): acquisitions fuel $7m revenue growth

Why fund managers backed Alkane Resources’ Mandalay merger (ASX:ALK)

NGE Capital: $20m Rio Tinto win boosts MLG OZ Ltd (ASX:MLG) valuation upside

Loading...

Why Fund Managers Back Greatland’s Telfer-Havieron Growth Story

Why fund managers back Black Cat Syndicate (ASX:BC8) after 57% rally and 100koz target

Fund managers on Openlearning (ASX:OLL): AI-powered low-cost LMS, 27% ARR growth & global university deals

Why fund managers are buying Neuren (ASX:NEU): Daybue value + NNZ-2591 Phase 3 upside

Frequently Asked Questions

Who is investing in Beamtree Holdings Ltd (ASX:BMT)?

Fund managers including Cyan Investment Management have invested in Beamtree Holdings Ltd (ASX:BMT).

Why do fund managers invest in Beamtree Holdings Ltd?

Fund managers invest in Beamtree Holdings Ltd due to its solid growth prospects in the healthcare sector, specifically in AI-based software and data insights. The company has shown operational progress, with a forecast for annual recurring revenue growth exceeding 20% for FY25 and aims for $60 million in ARR by the end of 2026. Recent collaborations and contracts, including partnerships with the NHS and installations in international markets, further enhance its appeal. However, the stock has experienced volatility, which reflects the risk/reward profile associated with such investments.

What happened to Beamtree Holdings Ltd (ASX:BMT)?

There have been no recent updates from fund managers regarding Beamtree Holdings Ltd although fund managers including Cyan Investment Management have previously commented.

What is the short interest in Beamtree Holdings Ltd (ASX:BMT)?

According to ASIC filings, there is negligible or no short interest in Beamtree Holdings Ltd (ASX:BMT).

What does Beamtree Holdings Ltd (ASX:BMT) do?

Beamtree Holdings Ltd. is an Australian healthcare technology company, which engages in the proprietary subscription based CDS called RippleDown that automates the human decision-making process within healthcare organizations based on rules set within the organization by domain experts. It operates through the following segments: Diagnostic Technology, Clinical Decision Support, Coding Assistance and Data Quality, and Analytics and Knowledge Networks. The Diagnostic Technology segment enables delivery of diagnostic services as they underpin the future of health and personalized medicine. The Clinical Decision Support segment combines human and artificial expertise together to enhance decisions that improve care, value and experience. The Coding Assistance and Data Quality segment is involved with digitizing and automating workflows with data, classification, coding & technical expertise to improve information standardization, quality and timeliness. The Analytics and Knowledge Networks segment is responsible for combining data analytics solutions with peer-to-peer alliances that accelerate innovation and knowledge diffusion. The company was founded on June 26, 2018, and is headquartered in Redfern, Australia.

faqs
q1
q2
q3
q4
q5

Newsletter Sign Up

Join the email list for updates.

Thesis-Tracker.com is Australia's largest professional investment commentary database. Thesis Tracker covers ASX listed companies with 5,000+ insights provided directly from financial services professionals. Thesis-Tracker.com does not enter into commercial arrangements with any of the featured financial services professionals nor publish proprietary opinions. Before making a decision please consider these and any relevant Product Disclosure Statement. Any advice on this site is general in nature and does not take into consideration your objectives, financial situation or needs.

bottom of page